Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) is now available.
JW (Cayman) Therapeutics Co. Ltd. has entered into a License Agreement with Juno, a substantial shareholder and connected person, to grant a non-exclusive license for its sLVV Manufacturing Process and related know-how for Juno’s cell therapy products globally. This transaction is classified as a connected transaction under Hong Kong’s Listing Rules, requiring independent shareholder approval due to the significant percentage ratio involved. An independent board committee and financial adviser have been appointed to guide shareholders, and an Extraordinary General Meeting (EGM) will be held to seek approval. Juno and its associates will abstain from voting, and the transaction’s effectiveness is contingent upon meeting listing requirements.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a company incorporated in the Cayman Islands, operating in the biotechnology sector with a focus on cell therapy products. The company engages in the development, commercialization, and manufacturing of cell therapy products, leveraging proprietary manufacturing processes and related know-how.
YTD Price Performance: 13.28%
Average Trading Volume: 2,060,118
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$603.4M
For detailed information about 2126 stock, go to TipRanks’ Stock Analysis page.